Research programme: cell cycle checkpoint activators - Merck & Co
Alternative Names: ARQ-150RP; ARQ-450RP; ARQ-800RPLatest Information Update: 20 Jan 2020
At a glance
- Originator ArQule
- Developer Merck & Co
- Class Small molecules
- Mechanism of Action Checkpoint kinase 2 stimulants; Checkpoint kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer